154 related articles for article (PubMed ID: 25708852)
1. Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Curr Med Res Opin; 2015 May; 31(5):975-86. PubMed ID: 25708852
[TBL] [Abstract][Full Text] [Related]
2. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Jun; 14(6):751-60. PubMed ID: 24666215
[TBL] [Abstract][Full Text] [Related]
3. Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Opin Drug Saf; 2014 Aug; 13(8):999-1008. PubMed ID: 24930544
[TBL] [Abstract][Full Text] [Related]
4. Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Dec; 14(12):1529-36. PubMed ID: 25159115
[TBL] [Abstract][Full Text] [Related]
5. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015 Jan; 15(1):129-41. PubMed ID: 25482593
[TBL] [Abstract][Full Text] [Related]
6. Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1229-42. PubMed ID: 25119858
[TBL] [Abstract][Full Text] [Related]
7. Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents.
Abdel-Rahman O; ElHalawani H
Crit Rev Oncol Hematol; 2016 Jun; 102():89-100. PubMed ID: 27129437
[TBL] [Abstract][Full Text] [Related]
8. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis.
Abdel-Rahman O; ElHalawani H
Expert Opin Drug Saf; 2015 Oct; 14(10):1495-506. PubMed ID: 26313327
[TBL] [Abstract][Full Text] [Related]
9. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
Abdel-Rahman O; ElHalawani H; Ahmed H; Ellithy M
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1433-45. PubMed ID: 26365425
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of dermatological toxicities associated with sorafenib.
Zhang L; Zhou Q; Ma L; Wu Z; Wang Y
Clin Exp Dermatol; 2011 Jun; 36(4):344-50. PubMed ID: 21507035
[TBL] [Abstract][Full Text] [Related]
11. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Crit Rev Oncol Hematol; 2015 Feb; 93(2):127-35. PubMed ID: 25139841
[TBL] [Abstract][Full Text] [Related]
12. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.
Abdel-Rahman O; ElHalawani H; Fouad M
Future Oncol; 2015; 11(17):2471-84. PubMed ID: 26274495
[TBL] [Abstract][Full Text] [Related]
13. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1063-73. PubMed ID: 24927771
[TBL] [Abstract][Full Text] [Related]
14. Proteinuria in Patients with Solid Tumors Treated with Ramucirumab: A Systematic Review and Meta-Analysis.
Abdel-Rahman O; ElHalawani H
Chemotherapy; 2014; 60(5-6):325-33. PubMed ID: 26302785
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
Nelson MH; Dolder CR
Ann Pharmacother; 2006 Feb; 40(2):261-9. PubMed ID: 16418322
[TBL] [Abstract][Full Text] [Related]
17. Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.
Hao S; Tian W; Gao B; Jiang Y; Zhang X; Zhang S; Guo L; Zhao J; Zhang G; Hu C; Yan J; Luo D
Oncotarget; 2017 Mar; 8(12):19923-19933. PubMed ID: 28199966
[TBL] [Abstract][Full Text] [Related]
18. Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
Lasheen S; Shohdy KS; Kassem L; Abdel-Rahman O
Expert Rev Anticancer Ther; 2017 Sep; 17(9):851-856. PubMed ID: 28699811
[TBL] [Abstract][Full Text] [Related]
19. Rash and Pruritus With PD-1 Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
Li J; Gu J
J Clin Pharmacol; 2019 Jan; 59(1):45-54. PubMed ID: 30088662
[TBL] [Abstract][Full Text] [Related]
20. Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials.
Santoni M; Conti A; Andrikou K; Bittoni A; Lanese A; Pistelli M; Pantano F; Vincenzi B; Armento G; Massari F; Tonini G; Cascinu S; Santini D
Crit Rev Oncol Hematol; 2015 Nov; 96(2):206-19. PubMed ID: 26070625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
